ADMA #VolatilityWatch by follow_the_money on TradingView.com Supply and demand trade that will make money, even in a Bear market. ADMA Biologics (Nasdaq: ADMA) is a great defensive play, … [Read more...] about ADMA Supply & Demand
technical analysis
Gene therapy treatment for SMA approved! (Full TA)
Gene Therapy for SMA-- Full technical analysis #VolatilityWatch by follow_the_money on TradingView.com RegenexBio (RGNX) and Novartis (NVS) just received FDA approval of Gene Therapy treatment for … [Read more...] about Gene therapy treatment for SMA approved! (Full TA)
Moving Averages; SMA & EMA Explained
Overview We have recently begun releasing educational pieces on technical strategies. The most recent article covering RSI got us thinking about other useful indicators for the less seasoned … [Read more...] about Moving Averages; SMA & EMA Explained
RSI and How You Can Leverage It
Key Points RSI can help you decide whether you should buy or sell RSI can help identify how undervalued/overvalued the stock is Background RSI; Relative Strength Index is a measure of recent … [Read more...] about RSI and How You Can Leverage It
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
ADMP Poised For NDA Approval
On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and … [Read more...] about ADMP Poised For NDA Approval
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Swing Trading a Biotech Stock
Overview Swing Trading is a trading strategy that involves buying a stock at a lower price and selling it at a higher price over a short period of time. Return on investment targets ranges from … [Read more...] about Swing Trading a Biotech Stock
You must be logged in to post a comment.